{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T18:34:22Z","timestamp":1773858862247,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Metabolic acidosis is a common complication in patients with chronic kidney disease (CKD). Oral sodium bicarbonate is often used to treat metabolic acidosis and prevent CKD progression. However, there is limited information about the effect of sodium bicarbonate on major adverse cardiovascular events (MACE) and mortality in patients with pre-dialysis advanced CKD.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> 25599 patients with CKD stage V between January 1, 2001 and December 31, 2019 were identified from the Chang Gung Research Database (CGRD), a multi-institutional electronic medical record database in Taiwan. The exposure was defined as receiving sodium bicarbonate or not. Baseline characteristics were balanced using propensity score weighting between two groups. Primary outcomes were dialysis initiation, all-cause mortality, and major adverse cardiovascular events (MACE) (myocardial infarction, heart failure, stroke). The risks of dialysis, MACE, and mortality were compared between two groups using Cox proportional hazards models. In addition, we performed analyzes using Fine and Gray sub-distribution hazard models that considered death as a competing risk.<\/jats:p><jats:p><jats:bold>Result:<\/jats:bold> Among 25599 patients with CKD stage V, 5084 patients (19.9%) were sodium bicarbonate users while 20515 (80.1%) were sodium bicarbonate non-users. The groups had similar risk of dialysis initiation (hazard ratio (HR): 0.98, 95% confidence interval (CI): 0.95-1.02, <jats:italic>p<\/jats:italic> &amp;lt; 0.379). However, taking sodium bicarbonate was associated with a significantly lower risks of MACE (HR: 0.95, 95% CI 0.92\u20130.98, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and hospitalizations for acute pulmonary edema (HR: 0.92, 95% CI 0.88\u20130.96, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) compared with non-users. The mortality risks were significantly lower in sodium bicarbonate users compared with sodium bicarbonate non-users (HR: 0.75, 95% CI 0.74\u20130.77, <jats:italic>p<\/jats:italic> &amp;lt; 0.001).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> This cohort study revealed that in real world practice, use of sodium bicarbonate was associated with similar risk of dialysis compared with non-users among patients with advanced CKD stage V. Nonetheless, use of sodium bicarbonate was associated with significantly lower rate of MACE and mortality. Findings reinforce the benefits of sodium bicarbonate therapy in the expanding CKD population. Further prospective studies are needed to confirm these findings.<\/jats:p>","DOI":"10.3389\/fphar.2023.1146668","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:03:10Z","timestamp":1683874990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Ya-Lien","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yun","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Li","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Hsing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Yi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Chung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1172\/JCI117668","article-title":"Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans","volume":"95","author":"Ballmer","year":"1995","journal-title":"J. Clin. Invest."},{"key":"B4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12882-016-0372-x","article-title":"Correction of metabolic acidosis improves insulin resistance in chronic kidney disease","volume":"17","author":"Bellasi","year":"2016","journal-title":"BMC Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12916-020-01542-9","article-title":"Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): A pragmatic randomised, double-blind, placebo-controlled trial","volume":"18","author":"Bi","year":"2020","journal-title":"BMC Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e27586","DOI":"10.1371\/journal.pone.0027586","article-title":"Activation of GPR4 by acidosis increases endothelial cell adhesion through the cAMP\/epac pathway","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS ONE"},{"key":"B7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1053\/j.ajkd.2014.07.007","article-title":"Serum bicarbonate and bone mineral density in US adults","volume":"65","author":"Chen","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/CIRCOUTCOMES.110.957951","article-title":"Landmark analysis at the 25-year landmark point","volume":"4","author":"Dafni","year":"2011","journal-title":"Circ. Cardiovasc Qual. Outcomes"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"de Brito-Ashurst","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/ndt\/gfz149","article-title":"Serum bicarbonate and cardiovascular events in hypertensive adults: Results from the systolic blood pressure intervention trial","volume":"35","author":"Dobre","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B11","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1053\/j.ajkd.2013.01.017","article-title":"Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: A report from the chronic renal insufficiency cohort (CRIC) study","volume":"62","author":"Dobre","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e001599","DOI":"10.1161\/JAHA.114.001599","article-title":"Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the chronic renal insufficiency cohort (CRIC) study","volume":"4","author":"Dobre","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e61991","DOI":"10.1371\/journal.pone.0061991","article-title":"Acidosis activation of the proton-sensing GPR4 receptor stimulates vascular endothelial cell inflammatory responses revealed by transcriptome analysis","volume":"8","author":"Dong","year":"2013","journal-title":"PLoS ONE"},{"key":"B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/ndt\/gfy214","article-title":"Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: A randomized controlled trial","volume":"35","author":"Dubey","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/j.1523-1755.2004.00481.x","article-title":"Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease","volume":"65","author":"Eustace","year":"2004","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2215\/CJN.02430312","article-title":"A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate","volume":"8","author":"Goraya","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1053\/j.ackd.2017.06.006","article-title":"Management of the metabolic acidosis of chronic kidney disease","volume":"24","author":"Goraya","year":"2017","journal-title":"Adv. Chronic Kidney Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1161\/01.cir.102.2.203","article-title":"Renal function, neurohormonal activation, and survival in patients with chronic heart failure","volume":"102","author":"Hillege","year":"2000","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jfma.2013.09.009","article-title":"Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database","volume":"114","author":"Hsieh","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/jcm8020208","article-title":"Oral bicarbonate therapy in non-haemodialysis dependent chronic kidney disease patients: A systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Hu","year":"2019","journal-title":"J. Clin. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1681\/ASN.V651386","article-title":"Spontaneous dietary protein intake during progression of chronic renal failure","volume":"6","author":"Ikizler","year":"1995","journal-title":"J. Am. Soc. Nephrol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40620-019-00656-5","article-title":"Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: The UBI study","volume":"32","author":"Iorio","year":"2019","journal-title":"J. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5049\/EBP.2014.12.2.80","article-title":"Effect of bicarbonate supplementation on renal function and nutritional indices in predialysis advanced chronic kidney disease","volume":"12","author":"Jeong","year":"2014","journal-title":"Electrolyte Blood Press"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00380118","article-title":"Effect of treatment of metabolic acidosis on vascular endothelial function in patients with CKD A pilot randomized cross-over study","volume":"13","author":"Kendrick","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B26","first-page":"1","article-title":"KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/ndt\/gfn633","article-title":"Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD","volume":"24","author":"Kovesdy","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"B28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.ajkd.2005.03.003","article-title":"Metabolic acidosis of CKD: Diagnosis, clinical characteristics, and treatment","volume":"45","author":"Kraut","year":"2005","journal-title":"Am. J. Kidney Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1159\/000508980","article-title":"The prevalence of metabolic acidosis in patients with different stages of chronic kidney disease: Single-centre study","volume":"45","author":"Kuczera","year":"2020","journal-title":"Kidney Blood Press Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","article-title":"Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: More accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions","volume":"55","author":"Levey","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"F1090","DOI":"10.1152\/ajprenal.00343.2020","article-title":"Alkali supplementation as a therapeutic in chronic kidney disease: What mediates protection?","volume":"319","author":"Mannon","year":"2020","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1053\/j.ajkd.2010.03.023","article-title":"Serum bicarbonate and long-term outcomes in CKD","volume":"56","author":"Menon","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1172\/JCI112020","article-title":"Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3","volume":"76","author":"Nath","year":"1985","journal-title":"J. Clin. Invest."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2215\/CJN.03730411","article-title":"Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease","volume":"6","author":"Navaneethan","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2215\/CJN.13091118","article-title":"Effects of treatment of metabolic acidosis in CKD: A systematic review and meta-analysis","volume":"14","author":"Navaneethan","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000328742","article-title":"Activation of intrarenal renin-angiotensin system during metabolic acidosis","volume":"34","author":"Ng","year":"2011","journal-title":"Am. J. Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-016-0462-x","article-title":"Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: The fremantle diabetes study","volume":"15","author":"Paul Chubb","year":"2016","journal-title":"Cardiovasc Diabetol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/sj.ki.5002647","article-title":"Dietary protein causes a decline in the glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin receptors","volume":"73","author":"Phisitkul","year":"2008","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"f6187","DOI":"10.1136\/bmj.f6187","article-title":"The relation between total joint arthroplasty and risk for serious cardiovascular events in patients with moderate-severe osteoarthritis: Propensity score matched landmark analysis","volume":"347","author":"Ravi","year":"2013","journal-title":"BMJ"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.4049\/jimmunol.1701605","article-title":"Oral NaHCO(3) activates a splenic anti-inflammatory pathway: Evidence that cholinergic signals are transmitted via mesothelial cells","volume":"200","author":"Ray","year":"2018","journal-title":"J. Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.atherosclerosis.2011.02.017","article-title":"Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease-a cross-sectional study of predialysis, dialysis and kidney-transplantation patients","volume":"216","author":"Recio-Mayoral","year":"2011","journal-title":"Atherosclerosis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.53\/j.ajkd.2015.03.032","article-title":"Serum bicarbonate and kidney disease progression and cardiovascular outcome in patients with diabetic nephropathy: A Post hoc analysis of the RENAAL (reduction of end points in non\u2013insulin-dependent diabetes with the angiotensin II antagonist losartan) study and IDNT (irbesartan diabetic nephropathy trial)","volume":"66","author":"Schutte","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","article-title":"The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan","volume":"28","author":"Shao","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1093\/ndt\/gfu388","article-title":"Angiotensin II-mediated GFR decline in subtotal nephrectomy is due to acid retention associated with reduced GFR","volume":"30","author":"Wesson","year":"2015","journal-title":"Nephrol. Dial. Transpl."},{"key":"B46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/sj.ki.5002036","article-title":"Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production","volume":"71","author":"Wesson","year":"2007","journal-title":"Kidney Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/ki.2010.348","article-title":"Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet","volume":"78","author":"Wesson","year":"2010","journal-title":"Kidney Int."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e112257","DOI":"10.1371\/journal.pone.0112257","article-title":"Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan","volume":"9","author":"Wu","year":"2014","journal-title":"PLoS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1146668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:03:15Z","timestamp":1683874995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1146668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":49,"alternative-id":["10.3389\/fphar.2023.1146668"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1146668","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"article-number":"1146668"}}